A Phase II trial of Atezolizumab (anti-PDL1) with Carboplatin in Patients with Metastatic Triple Negative Breast Cancer
The purpose of this study is to test how well the combination of study drugs, carboplatin and atezolizumab, keeps metastatic triple negative breast cancer from growing compared to taking carboplatin only.
This is an interventional randomized phase II trial studies how well carboplatin with or without atezolizumab works in treating patients with stage IV triple negative breast cancer.
Participants will not be paid for their participation.
- IRB Number: 1710788954 (TBCRC043)
- Research Study Identifier: TX8616
- Principal Investigator: Tarah Ballinger, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required